HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hydroquinone Marketer Ceases Shipments After Warning From Texas

This article was originally published in The Rose Sheet

Executive Summary

Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.

You may also be interested in...



Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says

Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.

CIR To Consider Re-Opening Safety Review Of Benzyl Alcohol Due To New Data

The Cosmetic Ingredient Review Expert Panel plans to evaluate new data regarding the inhalation toxicity of benzyl alcohol and benzoic acid during its next panel meeting June 28-29

Proposed Hydroquinone Ban Criticized In Literature Review

Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology

Related Content

UsernamePublicRestriction

Register

RS017598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel